Related references
Note: Only part of the references are listed.Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia
Rainer Claus et al.
BLOOD (2014)
Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations
John C. Riches et al.
BLOOD (2014)
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
Susan O'Brien et al.
LANCET ONCOLOGY (2014)
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment
Michael Hallek
AMERICAN JOURNAL OF HEMATOLOGY (2013)
NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome
N. Villamor et al.
LEUKEMIA (2013)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia
Davide Rossi et al.
BLOOD (2012)
Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial
Wolfgang U. Knauf et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
NOTCH1 mutations in+12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of+12 CLL
Ilaria Del Giudice et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Quantitative DNA Methylation Analysis Identifies a Single CpG Dinucleotide Important for ZAP-70 Expression and Predictive of Prognosis in Chronic Lymphocytic Leukemia
Rainer Claus et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997
Mitchell R. Smith et al.
BLOOD (2011)
Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712
Jennifer A. Woyach et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M. Hallek et al.
LANCET (2010)
ZAP-70 intron1 DNA methylation status: Determination by pyrosequencing in B chronic lymphocytic leukemia
Sylvain P. Chantepie et al.
LEUKEMIA RESEARCH (2010)
First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia
Barbara F. Eichhorst et al.
BLOOD (2009)
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
D. Catovsky et al.
LANCET (2007)
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997
Ian W. Flinn et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: Results from the US Intergroup Phase III Trial E2997
Michael R. Grever et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia
Maria Ilaria Del Principe et al.
BLOOD (2006)
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia
BF Eichhorst et al.
BLOOD (2006)
Immunoglobulin gene segment usage, location and immunogenicity in mutated and unmutated chronic lymphocytic leukaemia
K Mauerer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia
LZ Rassenti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile
A Wiestner et al.
BLOOD (2003)
ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia
M Crespo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Chromosome anomalies detected by interphase fluorescence in situ hybridization:: correlation with significant biological features of B-cell chronic lymphocytic leukaemia
GW Dewald et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia
DF Jelinek et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients
M Leporrier et al.
BLOOD (2001)
Genomic aberrations and survival in chronic lymphocytic leukemia.
H Döhner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
KR Rai et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
